Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC

Обзор

Intravenous vancomycin is considered first line therapy for serious methicillin-resistant Staphylococcus aureus (MRSA) infections including bacteremia, central nervous system infection, pneumonia, pleural space infection, bone or joint infection, prosthetic joint infection and deep abscesses. The effectiveness and toxicity of vancomycin depend on its dosing and chosen target. The most recent guidelines suggest targeting area under the curve over 24 hours over minimum inhibitory concentration (AUC/MIC) of 400 to 600. Implementation of AUC/MIC requires Bayesian software that can be variable, costly, complicated and time consuming. Ideally, AUC/MIC dosing would also require susceptibility testing by broth microdilution, which is not commonly done. It is recommended to target AUC of 400 to 600 assuming a MIC of 1ug/mL when MIC by broth microdilution is not known. Targeting a trough level of 10 to 15mg/L may be a reasonable and more practical alternative without compromising effectiveness. We will be conducting a randomized controlled non-inferiority trial to compare intravenous vancomycin dosing strategy targeting a trough level of 10 to 15mg/L versus AUC of 400 to 600 assuming a MIC of 1ug/mL by broth microdilution for serious MRSA infections. The primary outcome will be treatment failure, which is a composite of mortality and microbiologic failure at 90 days. We hypothesize that targeting a trough level of 10 to 15mg/L is non-inferior to targeting a AUC of 400 to 600 in terms of treatment failure. The criterion for non-inferiority is that a two-sided 95% confidence interval for difference in risk of treatment failure will lie within the non-inferiority margin of 10%.

Вмешательства

• Препарат Vancomycin
  Administration as outlined

Первичные конечные точки

• Treatment failure [Срок оценки: 90 days]

Вторичные конечные точки (6)

• Major adverse kidney events [Срок оценки: 90 days]
• Vancomycin associated nephrotoxicity [Срок оценки: 90 days]
• Renal replacement therapy [Срок оценки: 90 days]
• Time to target [Срок оценки: 90 days]
• Day 3 AUC [Срок оценки: 3 days]
• Vancomycin cost [Срок оценки: 90 days]

Критерии участия

Критерии включения

• Adult patients with serious MRSA infections based on culture results including bacteremia, pneumonia, pleural space infection, central nervous system infection, bone infection, septic arthritis, prosthetic joint infection, and deep abscess
• Enrolment within 4 days from date of MRSA culture collection
• Patient either currently not on vancomycin or has received vancomycin for 4 days or less

Критерии исключения

• Vancomycin minimum inhibitory concentration (MIC) ≥2ug/mL
• Patient is palliative or expected to die in the next 48 hours, or requires critical care resources but will not receive it due to advanced care directives
• History of type 1 hypersensitivity reaction to vancomycin
• Patients on intermittent hemodialysis or peritoneal dialysis

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Канада · 4 центра

• Hamilton Health Sciences — Hamilton
• St. Joseph's Healthcare Hamilton — Hamilton
• Kingston Health Sciences Centre — Kingston
• McGill University Health Centre — Montreal

Идентификаторы

NCT: NCT04793152 · 13327

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗